-
Redwood Bioscience: Tagging ADCs Redwood Bioscience Inc. Burlingame, Calif. Technology: Aldehyde tagging technology for antibody-drug conjugates and fusion proteins Disease focus: Cancer Clinical status: Research…
Published on 8/1/2011
-
Redwood Bioscience believes its site-specific aldehyde tagging technology will produce antibody-drug conjugates with a better therapeutic index than other ADCs in development.
Published on 8/1/2011
-
Resolve: Early answers, early exits Resolve Therapeutics LLC Seattle, Wash. Technology: Compounds targeting the interferon alpha pathway Disease focus: Autoimmune Clinical status: Preclinical Founded: 2010 by …
Published on 7/25/2011
-
Resolve's business model is to attract investors by allowing them to exit early in the clinical development process. It's trying the model first in lupus.
Published on 7/25/2011
-
SciFluor: Streamlining fluorination SciFluor Life Sciences LLC Boston, Mass. Technology: Fluorination of complex molecules to improve pharmaceutical properties Disease focus: N/A Clinical status: Preclinical …
Published on 7/25/2011
-
SciFluor expects its ability to add fluorine to complex molecules will translate into deals with partners looking either to rescue unsuccessful candidates, or to manage product lifecycles.
Published on 7/25/2011
-
Foundation Medicine: Panoramic profiling Foundation Medicine Inc. Cambridge, Mass. Technology: Molecular profiling of tumors Disease focus: Pharmacogenetics Clinical status: Marketed for research Founded: 2009 …
Published on 7/18/2011
-
Foundation Medicine has developed a technique to create a complete molecular profile of a patient's tumor in a single test, and has Celgene and Novartis among its early development partners
Published on 7/18/2011
-
Savira: Capping influenza Savira Pharmaceuticals GmbH Vienna, Austria Technology: Inhibitors of influenza viral polymerase and viral entry Disease focus: Infectious Clinical status: Preclinical Founded: 2009 by …
Published on 7/11/2011
-
Savira believes its influenza viral polymerase inhibitors can provide the therapeutic efficacy of neuraminidase inhibitors with less potential for resistance.
Published on 7/11/2011
-
ContraFect: Bringing down the walls ContraFect Corp. Yonkers, N.Y. Technology: Lysins and mAbs to treat infectious diseases, including those caused by Gram-positive bacteria and influenza Disease focus: Infectious…
Published on 7/4/2011
-
ContraFect's lysins attack the cell walls of Gram-positive bacteria and should enhance the effectiveness of conventional antibiotics.
Published on 7/4/2011
-
EpiTherapeutics: Built BRIC by BRIC EpiTherapeutics ApS Copenhagen, Denmark Technology: Compounds targeting histone demethylases and histone methyltransferases Disease focus: Cancer Clinical status: Preclinical …
Published on 6/27/2011
-
EpiTherapeutics believes access to a highly prolific Danish academic research engine allows it to produce compounds with increased specificity against new epigenetic targets, starting in cancer.
Published on 6/27/2011
-
Pathway: Function follows PI3K isoform Pathway Therapeutics Inc. San Francisco, Calif. Technology: Isoform-specific inhibitors of phosphoinositide 3-kinase to treat cancer and inflammatory disease Disease focus: …
Published on 6/20/2011
-
Pathway thinks its selective inhibitor of PI3K alpha and mTOR could treat solid tumors more effectively and safely than other PI3K inhibitors and the dual PI3K/mTOR inhibitors in development.
Published on 6/20/2011
-
Cyterix: CYPing on prodrugs Cyterix Pharmaceuticals Inc. San Francisco, Calif. Technology: OncoCYP cytochrome P450-targeted prodrug technology Disease focus: Cancer Clinical status: Preclinical Founded: 2010 by …
Published on 6/13/2011
-
Cyterix says its cancer prodrug technology is able to discriminate between healthy and tumor cells, while working in a range of tumor cell types.
Published on 6/13/2011
-
Indel identifies amino acid sequences that differ between human and bacterial versions of a protein, aiming to develop drugs against the bacterial version without unwanted side effects in humans.
Published on 6/6/2011
-
Indel: Vive la difference Indel Therapeutics Inc. Vancouver, B.C. Technology: Indel antimicrobial target identification Disease focus: Infectious Clinical status: Preclinical Founded: 2008 by Neil Reiner and …
Published on 6/6/2011
-
QR Pharma has in-licensed two compounds for Alzheimer's disease it believes have suffered from neglect rather than a lack of efficacy or safety.
Published on 5/30/2011
-
QR: Power of positivity QR Pharma Inc. Berwyn, Pa. Technology: Small molecules for Alzheimer's disease Disease focus: Neurology Clinical status: Phase I/II Founded: 2008 by Maria Maccecchini University …
Published on 5/30/2011
-
Otonomy: Delivering an earful Otonomy Inc. San Diego, Calif. Technology: Sustained-release drug delivery technology for the inner and middle ear Disease focus: Drug delivery, Infectious, Other Clinical status: …
Published on 5/23/2011
-
Otonomy believes its sustained-release gel formulations of drugs for inner and middle ear disorders will result in more effective dosing and perhaps eliminate the need for surgical intervention in some patients.
Published on 5/23/2011
-
Andes Biotechnologies believes that targeting non-coding mitochondrial RNA can reinstate apoptosis in tumor cells without being toxic to healthy cells.
Published on 5/16/2011